HLB Life Science Statistics
Total Valuation
HLB Life Science has a market cap or net worth of KRW 1.22 trillion. The enterprise value is 1.27 trillion.
Market Cap | 1.22T |
Enterprise Value | 1.27T |
Important Dates
The next estimated earnings date is Wednesday, March 19, 2025.
Earnings Date | Mar 19, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
HLB Life Science has 121.81 million shares outstanding. The number of shares has increased by 0.22% in one year.
Current Share Class | n/a |
Shares Outstanding | 121.81M |
Shares Change (YoY) | +0.22% |
Shares Change (QoQ) | +8.42% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | 6.75% |
Float | 97.91M |
Valuation Ratios
The trailing PE ratio is 14.93.
PE Ratio | 14.93 |
Forward PE | n/a |
PS Ratio | 10.92 |
PB Ratio | 2.75 |
P/TBV Ratio | 3.21 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | 17.92 |
EV / Sales | 13.11 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -21.70 |
Financial Position
The company has a current ratio of 1.36, with a Debt / Equity ratio of 0.38.
Current Ratio | 1.36 |
Quick Ratio | 1.28 |
Debt / Equity | 0.38 |
Debt / EBITDA | n/a |
Debt / FCF | -2.80 |
Interest Coverage | -1.31 |
Financial Efficiency
Return on equity (ROE) is 21.64% and return on invested capital (ROIC) is -3.48%.
Return on Equity (ROE) | 21.64% |
Return on Assets (ROA) | -3.36% |
Return on Capital (ROIC) | -3.48% |
Revenue Per Employee | 669.72M |
Profits Per Employee | 489.98M |
Employee Count | 145 |
Asset Turnover | 0.19 |
Inventory Turnover | 14.55 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -14.77% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | -14.77% |
50-Day Moving Average | 9,507.80 |
200-Day Moving Average | 11,798.65 |
Relative Strength Index (RSI) | 58.47 |
Average Volume (20 Days) | 414,066 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HLB Life Science had revenue of KRW 97.11 billion and earned 71.05 billion in profits. Earnings per share was 671.75.
Revenue | 97.11B |
Gross Profit | -3.20B |
Operating Income | -27.60B |
Pretax Income | 74.38B |
Net Income | 71.05B |
EBITDA | -21.34B |
EBIT | -27.60B |
Earnings Per Share (EPS) | 671.75 |
Balance Sheet
The company has 113.62 billion in cash and 164.62 billion in debt, giving a net cash position of -51.00 billion or -418.70 per share.
Cash & Cash Equivalents | 113.62B |
Total Debt | 164.62B |
Net Cash | -51.00B |
Net Cash Per Share | -418.70 |
Equity (Book Value) | 433.60B |
Book Value Per Share | 3,650.80 |
Working Capital | 36.33B |
Cash Flow
In the last 12 months, operating cash flow was -30.36 billion and capital expenditures -28.33 billion, giving a free cash flow of -58.69 billion.
Operating Cash Flow | -30.36B |
Capital Expenditures | -28.33B |
Free Cash Flow | -58.69B |
FCF Per Share | -481.81 |
Margins
Gross margin is -3.29%, with operating and profit margins of -28.42% and 73.16%.
Gross Margin | -3.29% |
Operating Margin | -28.42% |
Pretax Margin | 76.60% |
Profit Margin | 73.16% |
EBITDA Margin | -21.98% |
EBIT Margin | -28.42% |
FCF Margin | n/a |
Dividends & Yields
HLB Life Science does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -0.22% |
Shareholder Yield | -0.22% |
Earnings Yield | 6.70% |
FCF Yield | -4.80% |
Stock Splits
The last stock split was on December 28, 2022. It was a forward split with a ratio of 1.0516983.
Last Split Date | Dec 28, 2022 |
Split Type | Forward |
Split Ratio | 1.0516983 |
Scores
HLB Life Science has an Altman Z-Score of 4.63.
Altman Z-Score | 4.63 |
Piotroski F-Score | n/a |